Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 11/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6071908 | 0.89 | SLC18A3 (0.54) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL6072181 | 0.82 | SLC18A3 (0.56) | SLC18A3CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL6072071 | 0.81 | SLC18A3 (0.62) | SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL6072199 | 0.80 | UBE2M (0.49) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL9980730 | 0.79 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL8438595 | 0.79 | SLC18A3 (0.79) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL29418998 | 0.79 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL6071622 | 0.78 | ALDH1A1 (0.44) | SLC18A3SMN1; SMN2SIGMAR1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6071612 | 0.77 | SLC18A3 (0.54) | SLC18A3CYP1A2CYP2C9ALDH1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL6071855 | 0.77 | SLC18A3 (0.45) | SLC18A3CYP2D6CYP1A2CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | SLC18A3 2263/4885CYP2D6 2604/4885TSHR 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.